2024 World Conference on Lung Cancer (WCLC) - Posters-P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials

P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials

Back to course

Pdf Summary

The study titled "TCR Metrics as Predictive Biomarkers of Response and Survival After Perioperative Chemoimmunotherapy" examines the effectiveness of TCR (T-cell receptor) metrics as biomarkers for predicting treatment outcomes in non-small cell lung cancer (NSCLC). This research was conducted as part of the NADIM and NADIM II trials.<br /><br />The U.S. FDA has recently approved a combination of neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage resectable NSCLC, highlighting the demand for reliable biomarkers beyond TMB (tumor mutation burden) and PD-L1 expression due to their limited sensitivity.<br /><br />The study involved patients receiving either neoadjuvant chemoimmunotherapy or chemotherapy alone, analyzing tissue samples before and after treatment using the Oncomine TCR Beta-SR Assay. The aim was to explore TCR metrics such as convergence, evenness, and the top 1% clonal space as potential indicators of response.<br /><br />Results from the NADIM trials confirmed that pre-treatment TCR metrics have superior predictive value compared to traditional biomarkers like TMB and PD-L1. Specifically, TCR metrics were more accurate in forecasting complete pathological responses as well as progression-free survival (PFS) and overall survival (OS) rates.<br /><br />Furthermore, survival analyses indicate that TCR metrics provide better insights into PFS and OS than standard biomarkers. The findings suggest that these metrics are valuable for assessing the effectiveness of perioperative chemoimmunotherapy in NSCLC patients, warranting further investigation in larger populations.<br /><br />In conclusion, the study supports the use of TCR metrics as effective predictive biomarkers, enhancing the ability to tailor treatments for NSCLC patients. The research received funding from various sources, including Bristol-Myers Squibb and the European Union’s Horizon 2020 program.

Asset Subtitle

Cristina Martínez-Toledo

Meta Tag

Speaker Cristina Martínez-Toledo

Topic Local-Regional NSCLC

Keywords

TCR metrics

predictive biomarkers

NSCLC

chemoimmunotherapy

NADIM trials

neoadjuvant nivolumab

tumor mutation burden

PD-L1 expression

progression-free survival

overall survival